XRCC6 and lung carcinoma: The molecular mechanism of CAM is still unclear; however, it has been demonstrated that CAM increases of p53, FOXO3a and Ku70 acetylation level through SIRT1 and SIRT2 inhibition, and as a consequence sensitizes NCI H460 lung cancer cells to paclitaxel, drug which is commonly used also in TNBC chemotherapy (Figure 1) [17].